Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Traxoprodil. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B known ✓ | Q13224 | 6/20 | 1.00 |
| ▸ | GRIN1 known ✓ | Q05586 | 4/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 3/20 | 1.00 |
| ▸ | GRIN2D | O15399 | 3/20 | 1.00 |
| ▸ | GRIN2A | Q12879 | 3/20 | 1.00 |
| ▸ | GRIN2C | Q14957 | 3/20 | 1.00 |
| ▸ | GRIN3B | O60391 | 2/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 2/20 | 1.00 |
| ▸ | GRIN3A | Q8TCU5 | 2/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.59 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.59 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.59 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.59 |
| ▸ | ADRA2A | P08913 | 4/20 | 0.55 |
| ▸ | HTR2A | P28223 | 4/20 | 0.55 |
| ▸ | ADRA1A | P35348 | 4/20 | 0.55 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.55 |
| ▸ | HTR2B | P41595 | 3/20 | 0.55 |
| ▸ | HTR1A | P08908 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Traxoprodil SCHEMBL6800343 | 1.00 | GRIN2B (1.00) | GRIN2BGRIN1CYP2D6GRIN2DGRIN2A | |
| Traxoprodil SCHEMBL4248 | 1.00 | GRIN2B (1.00) | GRIN2BGRIN1CYP2D6GRIN2DGRIN2A | |
| Traxoprodil SCHEMBL8337144 | 1.00 | GRIN2B (1.00) | GRIN2BGRIN1CYP2D6GRIN2DGRIN2A | |
| Traxoprodil SCHEMBL6702711 | 1.00 | GRIN2B (1.00) | GRIN2BGRIN1CYP2D6GRIN2DGRIN2A | |
| Traxoprodil SCHEMBL5517640 | 1.00 | GRIN2B (1.00) | GRIN2BGRIN1CYP2D6GRIN2DGRIN2A | |
| Traxoprodil SCHEMBL8867900 | 0.99 | GRIN2B (0.97) | GRIN2BGRIN1CYP2D6GRIN2DGRIN2A | |
| Traxoprodil SCHEMBL8922418 | 0.99 | GRIN2B (0.97) | GRIN2BGRIN1CYP2D6GRIN2DGRIN2A | |
| Traxoprodil SCHEMBL8867888 | 0.99 | GRIN2B (0.97) | GRIN2BGRIN1CYP2D6GRIN2DGRIN2A | |
| Traxoprodil SCHEMBL27536541 | 0.93 | GRIN2B (0.86) | GRIN2BGRIN1CYP2D6GRIN2DGRIN2A | |
| Traxoprodil SCHEMBL7613753 | 0.93 | GRIN2B (0.86) | GRIN2BGRIN1CYP2D6GRIN2DGRIN2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1649857-A2 | New use of glutamate antagonists for the treatment of cancer | Ikonomidou, Hrissanthi (DE) | 2006-04-26 | — | — | EP | claimed |
| EP-1124553-A1 | NEW USE OF GLUTAMATE ANTAGONISTS FOR THE TREATMENT OF CANCER | Ikonomidou, Hrissanthi (DE) | 2001-08-22 | — | — | EP | claimed |
| EP-1002535-A1 | New use of glutamate antagonists for the treatment of cancer | Ikonomidou, Hrissanthi (DE) | 2000-05-24 | — | — | EP | claimed |
| WO-2000024395-A1 | NEW USE OF GLUTAMATE ANTAGONISTS FOR THE TREATMENT OF CANCER | IKONOMIDOU HRISSANTHI (DE) | 2000-05-04 | — | — | WO | claimed |
| EP-0398578-B1 | 2-piperidino-1-alkanol derivatives as antiischemic agents | PFIZER (US) | 1997-03-12 | — | — | EP | claimed |
| US-5272160-A | 2-piperidino-1-alkanol derivatives as antiischemic agents | PFIZER INC (US) | 1993-12-21 | — | — | US | claimed |
| US-7019016-B2 | Therapy of sensorineural hearing loss in a mammal by administering NR2B subunit selective N-methyl-D-aspartate (NMDA) NR2B subtype receptor antagonist | PFIZER INC (US) | 2006-03-28 | — | — | US | disclosed |
| US-6958351-B2 | NMDA NR2B antagonists for treatment | PFIZER INC (US) | 2005-10-25 | — | — | US | disclosed |
| US-20040162312-A1 | NMDA NR2B antagonists for treatment | PFIZER PRODUCTS INC. | 2004-08-19 | — | — | US | disclosed |
| US-20020072538-A1 | NMDA NR2B antagonists for treatment | PFIZER INC. | 2002-06-13 | — | — | US | disclosed |
| US-6008233-A | TREATING DISORDERS OF THE CENTRAL NERVOUS SYSTEM | PFIZER INC (US) | 1999-12-28 | — | — | US | disclosed |
| US-5696126-A | Prodrug esters of phenolic 2-piperidino-1-alkanols | PFIZER INC. (US) | 1997-12-09 | — | — | US | disclosed |
| EP-0485636-B1 | INDOLE DERIVATIVE | TORAY INDUSTRIES (JP) | 1997-03-12 | — | — | EP | disclosed |
| US-5338754-A | 2-pyrrolidino-1-alkanol derivatives as antiischemic agents | PFIZER INC (US) | 1994-08-16 | — | — | US | disclosed |
| US-5272160-A | 2-piperidino-1-alkanol derivatives as antiischemic agents | PFIZER INC (US) | 1993-12-21 | — | — | US | disclosed |
| US-5244904-A | Immunorepressant, analgesic | TORAY INDUSTRIES, INC. (JP) | 1993-09-14 | — | — | US | disclosed |
| US-5185343-A | NORTROPYL-1-ALKANOL DERIVATIVES AS ANTIISCHEMIC AGENTS | PFIZER INC. (US) | 1993-02-09 | — | — | US | disclosed |
| EP-0485636-A1 | INDOLE DERIVATIVE | TORAY INDUSTRIES, INC. (JP) | 1992-05-20 | — | — | EP | disclosed |
| WO-1990014088-A1 | 2-PIPERIDINO-1-ALKANOL DERIVATIVES AS ANTIISCHEMIC AGENTS | PFIZER INC. (US) | 1990-11-29 | — | — | WO | disclosed |
| EP-0398578-A2 | 2-piperidino-1-alkanol derivatives as antiischemic agents | PFIZER INC. (US) | 1990-11-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040162312-A1 | NMDA NR2B antagonists for treatment | GRIN2B, GRIN2A, GRIN1 | GRIN2B 1/4885GRIN1 3/4885CYP2D6 4483/4885 |
| US-20020072538-A1 | NMDA NR2B antagonists for treatment | GRIN2B, GRIN2A, GRIN1 | GRIN2B 1/4885GRIN1 3/4885CYP2D6 4483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.